Granulocyte colony-stimulating factor therapy reduces hospitalizations and improves chemotherapy administration in elderly breast cancer patients, but increases overall Medicare costs during first year of therapy.
Suja S. Rajan, MHA, MS, PhD
Advertisement
Articles by Suja S. Rajan, MHA, MS, PhD
Advertisement
Latest Updated Articles
- Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy
Published: February 13th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
